Cargando…

Decrease in Hospitalizations for Pneumonia in Children under Five Years of Age in an Indian Reservation in Panama after the Introduction of the Heptavalent Pneumococcal Conjugate Vaccine (PCV7)

This study quantifies the impact of Heptavalent-Pneumococcal Conjugate Vaccine (PCV7) in Panama on indigenous children younger than 5 years old, based on clinical pneumonia cases. This study demonstrates a significant 41.2% reduction in hospitalizations and 38.6% reduction in referrals for pneumonia...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nieto Guevara, Javier, Daza, Carlos, Smith, Rebecca
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2013
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3665215/ https://www.ncbi.nlm.nih.gov/pubmed/23762081 http://dx.doi.org/10.1155/2013/514578

Ejemplares similares

Biofilm-Forming Bacteria Implicated in Complex Otitis Media in Children in the Post-Heptavalent Pneumococcal Conjugate Vaccine (PCV7) Era
por: Ioannidis, Anastasios, et al.
Publicado: (2023)

Dynamic models of pneumococcal carriage and the impact of the Heptavalent Pneumococcal Conjugate Vaccine on invasive pneumococcal disease
por: Melegaro, Alessia, et al.
Publicado: (2010)

Effect of heptavalent pneumococcal conjugate vaccination on invasive pneumococcal disease in preterm born infants
por: Rückinger, Simon, et al.
Publicado: (2010)

Streptococcus pneumoniae colonisation in children and adolescents with asthma: impact of the heptavalent pneumococcal conjugate vaccine and evaluation of potential effect of thirteen-valent pneumococcal conjugate vaccine
por: Esposito, Susanna, et al.
Publicado: (2016)

Exploring the evidence behind the comparable impact of the pneumococcal conjugate vaccines PHiD-CV and PCV13 on overall pneumococcal disease
por: Izurieta, Patricia, et al.
Publicado: (2021)

Effectiveness and cost-effectiveness of general immunisation of infants and young children with the heptavalent conjugated pneumococcal vaccine
por: Antony, Katja, et al.
Publicado: (2005)

Antimicrobial Resistance among Isolates Causing Invasive Pneumococcal Disease before and after Licensure of Heptavalent Conjugate Pneumococcal Vaccine
por: Karnezis, Tom Theodore, et al.
Publicado: (2009)

Response to article by Johnna Perdrizet et al.,“Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants”
por: Gómez, Jorge A., et al.
Publicado: (2021)

1480. Incidence of Non-Invasive Pneumococcal Pneumonia in Children in the United States before and after Introduction Pneumococcal Conjugate Vaccines (PCV7 and PCV13) during 1998-2018
por: Hu, Tianyan, et al.
Publicado: (2020)

Impact of Switch Options on the Economics of Pneumococcal Conjugate Vaccine (PCV) Introduction in Indonesia
por: Suwantika, Auliya A., et al.
Publicado: (2020)

Five winters of pneumococcal serotype replacement in UK carriage following PCV introduction
por: Gladstone, Rebecca A., et al.
Publicado: (2015)

Impact on respiratory tract infections of heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 11 months of age
por: Esposito, Susanna, et al.
Publicado: (2007)

Nasopharyngeal Carriage of Streptococcus pneumoniae in Healthy Children: Implications for the Use of Heptavalent Pnemococcal Conjugate Vaccine
por: Marchisio, Paola, et al.
Publicado: (2002)

Decrease of Pneumococcal Community-Acquired Pneumonia Hospitalization and Associated Complications in Children after the Implementation of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) in Taiwan
por: Shen, Ching-Fen, et al.
Publicado: (2021)

Reply to ‘Emergence of Streptococcus pneumoniae serotype 19A (Spn19A) in the pediatric population in Bogotá, Colombia as the main cause of invasive pneumococcal disease after the introduction of PCV10’
por: Nieto Guevara, Javier, et al.
Publicado: (2020)

Population genomics of pneumococcal carriage in South Africa following the introduction of the 13-valent pneumococcal conjugate vaccine (PCV13) immunization
por: Javaid, Nida, et al.
Publicado: (2022)

Public Health Value of a Hypothetical Pneumococcal Conjugate Vaccine (PCV) Introduction: A Case Study
por: Chaiyakunapruk, Nathorn, et al.
Publicado: (2022)

Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants
por: Perdrizet, Johnna, et al.
Publicado: (2020)

Estimating the Clinical and Economic Impact of Switching from the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) to the 10-Valent Pneumococcal Conjugate Vaccine (PCV10) in Italy
por: Ansaldi, Filippo, et al.
Publicado: (2020)

ENT/Audiology Department of Samoa welcomes the introduction of the Pneumococcal Conjugate Vaccine (PCV) into the national childhood immunisation program.
por: Kaspar, Annette, et al.
Publicado: (2022)

Sortase-click strategy for defined protein conjugation on a heptavalent cyclodextrin scaffold
por: Singh, Shikha, et al.
Publicado: (2019)

Serotype-specific effectiveness against pneumococcal carriage and serotype replacement after ten-valent Pneumococcal Conjugate Vaccine (PCV10) introduction in Pakistan
por: Nisar, Muhammad Imran, et al.
Publicado: (2022)

1180. Comparing Changes in Pneumococcal Meningitis Incidence to all Invasive Pneumococcal Disease Following Introduction of PCV10 and PCV13: The PSERENADE Project
por: Yang, Yangyupei, et al.
Publicado: (2021)

Changes in Invasive Pneumococcal Disease Caused by Streptococcus pneumoniae Serotype 1 following Introduction of PCV10 and PCV13: Findings from the PSERENADE Project
por: Bennett, Julia C., et al.
Publicado: (2021)

Effectiveness of Pneumococcal Conjugate Vaccines (PCV7 and PCV13) against Invasive Pneumococcal Disease among Children under Two Years of Age in Germany
por: van der Linden, Mark, et al.
Publicado: (2016)

Letter to the Editor Regarding: “Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants”
por: Gomez, Jorge A., et al.
Publicado: (2022)

Pneumococcal Meningitis in Adults after Introduction of PCV7 and PCV13, Israel, July 2009–June 2015
por: Regev-Yochay, Gili, et al.
Publicado: (2018)

1479. Incidence of Acute Otitis Media in Children in the United States before and after the introduction of Pneumococcal Conjugate Vaccines (PCV7 and PCV13) during 1998-2018
por: Hu, Tianyan, et al.
Publicado: (2020)

HIV Infection and the Epidemiology of Invasive Pneumococcal Disease (IPD) in South African Adults and Older Children Prior to the Introduction of a Pneumococcal Conjugate Vaccine (PCV)
por: Meiring, Susan, et al.
Publicado: (2016)

Comparison of early effects of pneumococcal conjugate vaccines: PCV7, PCV10 and PCV13 on Streptococcus pneumoniae nasopharyngeal carriage in a population based study; The Palestinian-Israeli Collaborative Research (PICR)
por: Abu Seir, Rania, et al.
Publicado: (2018)

Aetiology of paediatric pneumonia after the introduction of pneumococcal conjugate vaccine
por: Elemraid, Mohamed A., et al.
Publicado: (2013)

Pneumococcal carriage among children under five in Accra, Ghana, five years after the introduction of pneumococcal conjugate vaccine
por: Dayie, Nicholas T. K. D., et al.
Publicado: (2019)

Impact of Pneumococcal Conjugate Vaccines on the Incidence of Pneumonia in Hospitalized Children after Five Years of Its Introduction in Uruguay
por: Hortal, María, et al.
Publicado: (2014)

Effectiveness of 13-pneumococcal conjugate vaccine (PCV13) against invasive pneumococcal disease in children in the Dominican Republic
por: Tomczyk, Sara, et al.
Publicado: (2018)

Invasive pneumococcal surveillance to assess the potential benefits of extended spectrum conjugate vaccines (PCV15/PCV20) in older adults
por: Humphreys, Hilary, et al.
Publicado: (2023)

Population genomics of pneumococcal carriage in Massachusetts children following introduction of PCV-13
por: Mitchell, Patrick K., et al.
Publicado: (2019)

1474. Impact of 13-valent Pneumococcal Conjugate Vaccine (PCV13) on Non-bacteremic Pneumococcal Pneumonia (NBPP) among Adults in the United States, 2013-2017
por: Gierke, Ryan, et al.
Publicado: (2020)

The Impact of Pneumococcal Conjugate Vaccine (PCV) Coverage Heterogeneities on the Changing Epidemiology of Invasive Pneumococcal Disease in Switzerland, 2005–2019
por: Oyewole, Oluwaseun Rume-Abiola, et al.
Publicado: (2021)

Assessing the efficiency of catch-up campaigns for the introduction of pneumococcal conjugate vaccine: a modelling study based on data from PCV10 introduction in Kilifi, Kenya
por: Flasche, Stefan, et al.
Publicado: (2017)

2703. Pneumococcal Carriage of 13-Valent Pneumococcal Conjugate Vaccine (PCV13) and Non-PCV13 Serotypes among Greek Children Vaccinated with PCV13 in a 3 + 1 Schedule During the First 6 years after the Fourth Dose of PCV13
por: Syrogiannopoulos, George A, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_r8cb71vrb7tc9j0mrd3806pfdk